



Emerging Trends and Drug Treatments in Oral Oncology

Guest Editors:

Prof. Dr. Hsueh-Wei Chang

Department of Biomedical
Science and Environmental
Biology, Kaohsiung Medical
University, Kaohsiung, Taiwan

Prof. Dr. Chien-Chih Chiu

Department of Biotechnology,
Kaohsiung Medical University,
Kaohsiung, Taiwan

Deadline for manuscript
submissions:

closed (15 December 2022)

Message from the Guest Editors

Dear Colleagues,

Oral cancer is increasing annually for both genders. Mounting reports demonstrate that more sensitive and novel technologies are developed to detect oral cancer. This improvement provides an early diagnosis of oral cancer and may reduce its death rate. Moreover, several synthetic drugs and natural products were rapidly discovered against different cancers, enhancing their applications for oral cancer treatments. Moreover, combined treatments or natural product extracts (with defined molecular compound) have the potential for multiple targeting against oral cancer treatments. Drugs showing different types of cell deaths are also welcome, providing numerous choices for oral cancer treatment. Therefore, the novel detection and drug discovery against oral cancer warrant a detailed investigation.

This Special Issue aims to host research and review papers on developing novel methodology and technology for oral cancer detection and identifying novel drug treatment or combined treatment for antiproliferation purposes of oral cancer cells. This holds a great promise for improved oral cancer detection and remedies in the future.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)